share_log

Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences開始治療卵巢癌CAR-T臨床試驗中的第五名患者
Anixa Biosciences ·  05/21 12:00

Novel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid tumors

新的專有CAR-T方法有可能成爲第一種有效的實體瘤CAR-T療法

SAN JOSE, Calif., May 21, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that treatment has commenced for the fifth patient in its ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center.

加利福尼亞州聖何塞,2024 年 5 月 21 日 /PRNewswire/-- Anixa Biosciences, Inc (“Anixa” 或 “公司”)(納斯達克股票代碼:ANIX)是一家專注於癌症治療和預防的臨床階段生物技術公司,今天宣佈,正在進行的卵巢癌新型嵌合抗原受體T細胞(CAR-T)療法的1期臨床試驗中,第五名患者的治療已經開始。該研究是通過與莫菲特癌症中心的研究合作進行的。

Anixa's first-in-human trial (NCT05316129) is enrolling female adult patients with recurrent/progressing ovarian cancer who were unresponsive to at least two prior therapies. Safety was confirmed in the first three-patient cohort. The patients in the second cohort, including patient #5, receive triple the dose of engineered T-cells compared with the first cohort of three patients. The study will identify the maximum tolerated dose of T-cells targeting the follicle stimulating hormone receptor (FSHR), found only on ovarian cells

Anixa 的首次人體試驗 (NCT05316129)正在招收對至少兩種先前療法沒有反應的復發/進展性卵巢癌的女性成年患者。在前三名患者中,安全性得到證實。與第一組三名患者相比,第二組患者,包括患者 #5,接受的工程T細胞劑量是第一組患者的三倍。該研究將確定靶向卵泡刺激素受體(FSHR)的T細胞的最大耐受劑量,該受體僅存在於卵巢細胞上

"With our fifth patient treated, our trial is progressing, and we continue to see that our therapy appears to be safe and well-tolerated," said Dr. Amit Kumar, Chairman and CEO of Anixa. "The technology behind our novel CAR-T therapy differs from traditional CAR-T therapies by targeting the FSHR, which research indicates is exclusively expressed on ovarian cells in healthy adult females. We developed this approach to tackle preexisting difficulties with CAR-T cell therapies in solid ovarian tumors. In our trial, we will also explore several parameters for applying our CAR-T therapy to solid tumors in general."

Anixa董事長兼首席執行官阿米特·庫馬爾博士說:“隨着我們的第五名患者接受了治療,我們的試驗正在取得進展,我們繼續看到我們的療法似乎是安全且耐受性良好的。”“我們的新型CAR-T療法背後的技術與傳統的CAR-T療法不同,它以FSHR爲目標,研究表明,FSHR僅在健康成年女性的卵巢細胞上表達。我們開發這種方法是爲了解決實體卵巢腫瘤中CAR-T細胞療法先前存在的困難。在我們的試驗中,我們還將探索將我們的CAR-T療法應用於一般實體瘤的幾個參數。”

Anixa's FSHR-mediated CAR-T technology was developed by Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine. Anixa holds an exclusive world-wide license to the technology from The Wistar Institute.

Anixa的FSHR介導的CAR-T技術由杜克大學醫學院綜合免疫生物學系免疫學教授何塞·科內霍-加西亞醫學博士、博士開發。Anixa持有Wistar研究所對該技術的全球獨家許可。

About Anixa's CER-T Approach (Follicle Stimulating Hormone Receptor-Mediated CAR-T technology)
Anixa's chimeric antigen receptor T-cell (CAR-T) technology approach is an autologous cell therapy comprised of engineered T-cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone (chimeric endocrine) receptor, and the target-binding domain is derived from its natural ligand, this technology is known as CER-T (chimeric endocrine receptor T-cell) therapy, a new type of CAR-T.

關於 Anixa 的 CER-T 方法(卵泡刺激激素受體介導的 CAR-T 技術)
Anixa 的嵌合抗原受體 T 細胞 (CAR-T) 技術方法是一種自體細胞療法,由靶向卵泡刺激激素受體 (FSHR) 的工程化 T 細胞組成。FSHR 僅存在於卵巢顆粒細胞的免疫學相關水平。由於靶點是激素(嵌合內分泌)受體,並且靶結合域源自其天然配體,因此該技術被稱爲 CER-T(嵌合內分泌受體 T 細胞)療法,一種新型的 CAR-T。

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.

關於 Anixa Biosciences, Inc.
Anixa是一家臨床階段的生物技術公司,專注於癌症的治療和預防。Anixa的治療產品組合包括與莫菲特癌症中心合作開發的卵巢癌免疫療法計劃,該計劃使用一種新型的CAR-T,即嵌合內分泌受體T細胞(CER-T)技術。該公司的疫苗產品組合包括與克利夫蘭診所合作開發的預防乳腺癌(特別是三陰性乳腺癌(TNBC),該疾病中最致命的形式)和卵巢癌的疫苗,以及其他用於治療許多難治癌症的癌症疫苗,包括肺部、結腸和前列腺的高發惡性腫瘤。這些疫苗技術側重於對已發現可在某些形式的癌症中表達的 “退役” 蛋白進行免疫接種。Anixa在各個開發階段與世界知名研究機構合作的獨特商業模式使公司能夠不斷研究互補領域的新興技術,以進一步開發和商業化。要了解更多信息,請訪問 www.anixa.com 或者繼續關注 Anixa 推特領英Facebook優酷

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward- looking statements when evaluating the information presented in this press release.

前瞻性陳述:根據1995年《私人證券訴訟改革法》,非歷史事實的陳述可能被視爲前瞻性陳述。前瞻性陳述不是對歷史事實的陳述,而是反映了Anixa當前對未來事件和結果的預期。我們通常使用 “相信”、“期望”、“打算”、“計劃”、“預期”、“可能”、“將” 等詞語以及類似的表述來識別前瞻性陳述。此類前瞻性陳述,包括與我們的預期有關的陳述,涉及風險、不確定性和其他因素,其中一些因素是我們無法控制的,這可能導致我們的實際業績、業績或成就或行業業績與此類前瞻性陳述所表達或暗示的任何未來業績、業績或成就存在重大差異。這些風險、不確定性和因素包括但不限於 “項目1A——風險因素” 和我們最新的10-K表年度報告以及我們的10-Q表季度報告和8-K表最新報告的其他部分中列出的因素。除非法律要求,否則我們沒有義務公開更新或修改任何前瞻性陳述,無論是由於新信息、未來事件還是其他原因。提醒您在評估本新聞稿中提供的信息時不要過度依賴此類前瞻性陳述。

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

聯繫人:
邁克·卡特拉尼
總裁、首席運營官兼首席財務官
mcatelani@anixa.com
408-708-9808

SOURCE  Anixa Biosciences, Inc.

來源 Anixa Biosciences, Inc.

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論